Specific Antisense Oligomer Anti Bcr-abl Junctions in Chronic Myeloid Leukemia: A Cell Cycle Analysis and CFU-GM Study

References

• Nowell P. C., Hungerford D. A. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497
   Web of Science ®Google Scholar
• Fialkow P. I., Jacobson R. I., Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to granulocyte, erythrocyte, platelet and monocyte/macrophage. Amer. J. Med. 1977; 63: 125–130
   PubMed Web of Science ®Google Scholar
• Groffen J., Stephenson I. R., Heisterkamp N. Philadelphia chromosomal breakpoint clustered within a limited region bcr on chromosome 22. Cell 1984; 36: 93–98
   PubMed Web of Science ®Google Scholar
• Van Etten R. A., Jackson P., Baltimore D. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 1989; 58: 696–675
   Web of Science ®Google Scholar
• Shtivelman E., Lifshitz B., Gale R. P., Cananii E. Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature 1985; 315: 550–554
   PubMed Web of Science ®Google Scholar
• Lugo T. G., Pendergast A. M., Mulle A. J., Witte O. N. Tyrosine kinase activity and transformation potency of BCR-ABL oncogene products. Science 1990; 247: 1079–1082
   PubMed Web of Science ®Google Scholar
• Daley G. Q., Van Ette R. A., Baltimore D. Induction of chronic inyelogenour leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824–830
   PubMed Web of Science ®Google Scholar
• Goldman J. M. Options for the management of chronic myeloid leukaemia. Leukemia Lymphoma 1990; 3: 159–165
   PubMed Web of Science ®Google Scholar
• Szczylik C., Skorski T., Nicolaides N. C., Manzella L., Malaguarneva L., Venturelli D., Gewirtz A. M., Calabretta B. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligonucleotides. Science 1991; 253: 562–565
   PubMed Web of Science ®Google Scholar
• Goldman J. M., Apperley J. F., Jones L. M., Marcus R. E., Goolden A. W. G., Batchelor J. R., Hale G., Waldmann H., Reid C. D., Hows J. M., Gordon-Smith E. C., Catowsky D., Galton D. A. G. Bone marrow transplantation for patients with chronic myeloid leukemia. N. Engl. J. Medicine 1986; 314: 202–207
   PubMed Web of Science ®Google Scholar
• Reiffers J., Trouette R., Marit G., Montastruc M., Faheres C., Cony-Makhoul P., David B., Bourdeau M. J., Bilhou Nahera C., Lacombe F., Feuillatre-Fabre F., Vezon G., Bernard Ph., Broustet A. Autologous blood stem cell transplantation for chronic granulocytic leukemia in transform:ition: a report of 47 cases. Brit. J. Haematol. 1991; 77: 339–345
   PubMed Web of Science ®Google Scholar
• Lacombe F., Belloc F., Bernard P., Boisseau M. R., Reiffers J. Evaluation of four methods of DNA distribution data analysis based on bromodeoxyuridine/DNA bivariate data. Cytometry 1988; 9: 245–253
   PubMedGoogle Scholar
• Lacombe F., Belloc F., Dumain P., Pintous M., Lopez F., Bernard P., Boisseau M. R., Reiffers J. Quantitation of resistance of leukemic cells to cytosine arabinoside from BrdUrd/DNA hivariate histograms. Cytometry 1992; 13: 730–738
   PubMedGoogle Scholar
• Mahon F. X., Daheron L., Malinge M. C., Ahmad M., Delfau M. H., Grandchamp B., Kitzis A., Tanzer J., Guilhol F. Polymerase chain reaction detection of residual disease in chronic myelocytic leukemia in complete cytogenetic; remission treated by interferon with or without chemotherapy. Leukemia 1992; 6: 1232–1239
   PubMed Web of Science ®Google Scholar
• Kirland M. A., O'Brien S., McDonald C., Davidson R. J., Cross N. C. P., Goldman J. BCR-ABL antisense purging in chronic myeloid leukemia. Lancet 1993; 342: 614
   Web of Science ®Google Scholar
• Carraciolo D., Valtieri M., Venturelli D., Peschle C., Gewirtz A. M., Calabretta B. Lineage specific requirement of c-abl function in normal hematopoiesis. Science 1989; 245: 1107–1110
   PubMed Web of Science ®Google Scholar
• Rosti V., Bergamaschi G., Ponchio L., Cazzola M. C-ABL function in normal and chronic myelogenous leukemia hematopoiesis: in vitro studies with antisense oligomers. Leukemia 1992; 6: 1–7
   PubMed Web of Science ®Google Scholar
• Ratajczak M. Z., Hijiya N., Catani L., De Riel K., Luger S. M., McGlave Ph., Gewiriz A. M. Acute and chronic phase chronic inyelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effectc of c-myb antisense. Blood 1992; 79: 1956–1961
   PubMed Web of Science ®Google Scholar
• Sawyers C. L., Callagan W., Witte O. N. Dominant negative MYC blocks transformation by ABL oncogene. Cell 1992; 70: 901–908
   PubMed Web of Science ®Google Scholar
• Ahuja H., Bar-Eli M., Arlin Z., Advani S., Allen S. L., Goldman J., Snydes D., Foti A., Cline M. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J. Clin. Invest. 1991; 87: 2042–2049
   PubMed Web of Science ®Google Scholar
• Towatari M., Adachi K., Kato H., Saito H. Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia. Blood 1991; 78: 2178–2181
   PubMed Web of Science ®Google Scholar
• Smetsers T., Skorski T., Van de Locht L., Wessels H., Pennings A., De Witte T., Calabretta B., Mensink E. Antisense BCK-ABL oligonucleotides induce apoptosis in the philadelphia Chromosome-positive cell line BV173. Leukemia 1994; 8: 129–143
   PubMed Web of Science ®Google Scholar
• Evans C., Owen-Lynch J., Whetton A., Dive C. Activation of Abelson tyrosine kinase activity is associated with suppression of apoptosis in hematopoietic cells. Cancer Res. 1993; 53: 1735–1738
   PubMed Web of Science ®Google Scholar
• Mahon F. X., Belloc F., Reiffers J. Antisense oligomers in chronic myeloid leukemia. Lancet 1993; 341: 566
   PubMed Web of Science ®Google Scholar
• McGlave P. B., Arthur D., Miller W. J., Lasky L., Kersey J. Autologous transplantation for CML using marrow treated ex vivo with recombinant human interferon gamma. Bone Marrow Transplant. 1990; 6: 115–121
   PubMed Web of Science ®Google Scholar
• Skorski T., Niehorowska-Skorska M., Barleta C., Malaguarnera L., Srczylick C., Chen S. T., Lange B., Calabretta B. Highly efficiency elimination of Philadelphia leukemic cells by exposure to bcr/ahl antisense oligodeoxynucleotidec combined with mafosfamide. J. Clin. Invest. 1993; 92: 194–202
   PubMed Web of Science ®Google Scholar
• Bedi A., Zehnbauer B. A., Collector M. I., Barber J. F., Zicha M. S., Sharkis S. J., Jones R. J. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood 1993; 81: 2898–2902
   PubMed Web of Science ®Google Scholar